Obstructive sleep apnea has been linked to an increased risk of dementia in a new study—and the association was particularly ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

Dementia, a term encompassing a decline in cognitive function, is a complex and often misunderstood condition.

The agency had previously recommended against marketing authorization for the Alzheimer's disease but reconsidered after a review.

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Participants will learn: • How Alzheimer’s disease affects people. • The difference between Alzheimer’s and dementia. • The ...

Accidents can happen, and when they do, seniors are vulnerable to losing their independence. If you find yourself rushing to ...

“We need to do better. We need to ensure that these differences don’t exist.” Traditionally, research has shown the largest ...

nursing homes and differences between the two. Text Callout : key takeaways memory care vs. nursing home Memory care is a ...

Understand Alzheimer's disease Alzheimer's disease is the leading cause of dementia, accounting for approximately 80% of ...

A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...

Older adults whose cholesterol levels fluctuate from year to year may face an increased risk for dementia and cognitive ...